IDC 004
Alternative Names: IDC-004Latest Information Update: 12 May 2022
At a glance
- Originator Prestige BioPharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Angiogenesis inhibitors; PAUF protein inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Ovarian cancer; Pancreatic cancer
Most Recent Events
- 05 May 2022 Early research in Ovarian cancer in Singapore (Parenteral) (Prestige Biopharma pipeline, May 2022)
- 05 May 2022 Early research in Pancreatic cancer in Singapore (Parenteral) (Prestige Biopharma pipeline, May 2022)
- 05 May 2022 Prestige BioPharma plans regulatory submission to EMA and US FDA for Pancreatic cancer and Ovarian cancer in 2026